Orforglipron for obesity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 16 registered trials.

Why this status

  1. 3 Apr 2023: Trial started, NCT05803421
  2. 7 Apr 2023: Trial registered, NCT05803421
  3. 22 May 2023: Trial registered, NCT05869903
  4. 24 May 2023: Trial registered, NCT05872620
  5. 5 Jun 2023: Trial started, NCT05869903
  6. 5 Jun 2023: Trial started, NCT05872620
  7. 5 Jul 2023: Trial registered, NCT05931380
  8. 31 Jul 2023: Trial started, NCT05931380
  9. 5 Sep 2024: Trial registered, NCT06584916
  10. 13 Sep 2024: Trial started, NCT06584916
  11. 18 Oct 2024: Trial registered, NCT06649045
  12. 22 Oct 2024: Trial started, NCT06649045
  13. 4 Nov 2024: Trial registered, NCT06672939
  14. 18 Nov 2024: Trial started, NCT06672939
  15. 29 Apr 2025: Trial registered, NCT06948435
  16. 30 Apr 2025: Trial started, NCT06948435
  17. 15 May 2025: Trial registered, NCT06972459
  18. 15 May 2025: Trial started, NCT06972459
  19. 15 May 2025: Trial registered, NCT06972472
  20. 15 May 2025: Trial started, NCT06993792
  21. 19 May 2025: Trial started, NCT06972472
  22. 29 May 2025: Trial registered, NCT06993792
  23. 4 Sep 2025: Trial registered, NCT07153471
  24. 15 Sep 2025: Trial started, NCT07153471

The trials

NCT05051579: A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities

State
Completed
Phase
Phase 2
People
272 taking part
Started
29 Sep 2021
Primary completion
25 Aug 2022
Arms
12 milligram (mg) LY3502970, 24 mg LY3502970, 36 mg-1 LY3502970, 36 mg-2 LY3502970, 45 mg-1 LY3502970, 45 mg-2 LY3502970
Results
Posted on the registry
  1. 21 Sep 2021: Trial registered
  2. 29 Sep 2021: Trial started
  3. 22 Nov 2022: Trial completed
  4. 13 Sep 2023: Trial results posted

NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

State
Completed
Phase
Phase 3
People
2,749 taking part
Started
3 Apr 2023
Primary completion
16 Mar 2026
Arms
Orforglipron
Results
None posted
  1. 3 Apr 2023: Trial started
  2. 7 Apr 2023: Trial registered
  3. 16 Mar 2026: Trial completed

NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

State
Under way
Phase
Phase 3
People
3,127 taking part
Started
5 Jun 2023
Primary completion
25 Jul 2025
Arms
6 mg Orforglipron, 12 mg Orforglipron, 36 mg Orforglipron
Results
Posted on the registry
  1. 22 May 2023: Trial registered
  2. 5 Jun 2023: Trial started
  3. 14 Aug 2026: Trial results posted

NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

State
Completed
Phase
Phase 3
People
1,613 taking part
Started
5 Jun 2023
Primary completion
8 Aug 2025
Arms
6 mg Orforglipron QD, 12 mg Orforglipron QD, 36 mg Orforglipron QD
Results
Posted on the registry
  1. 24 May 2023: Trial registered
  2. 5 Jun 2023: Trial started
  3. 8 Aug 2025: Trial completed
  4. 4 Sep 2026: Trial results posted

NCT05931380: A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease

State
Completed
Phase
Phase 3
People
238 taking part
Started
31 Jul 2023
Primary completion
19 Jun 2025
Arms
6 mg Orforglipron QD, 12 mg Orforglipron QD, 36 mg Orforglipron QD
Results
Posted on the registry
  1. 5 Jul 2023: Trial registered
  2. 31 Jul 2023: Trial started
  3. 19 Jun 2025: Trial completed
  4. 20 Jul 2026: Trial results posted

NCT06023095: A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities

State
Completed
Phase
Phase 1
People
24 taking part
Started
21 Sep 2023
Primary completion
29 Jul 2024
Arms
LY3502970 (Cohort 1), LY3502970 (Cohort 2)
Results
Posted on the registry
  1. 5 Sep 2023: Trial registered
  2. 21 Sep 2023: Trial started
  3. 29 Jul 2024: Trial completed
  4. 17 Jul 2026: Trial results posted

NCT06584916: A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)

State
Completed
Phase
Phase 3
People
376 taking part
Started
13 Sep 2024
Primary completion
21 Nov 2025
Arms
Orforglipron
Results
None posted
  1. 5 Sep 2024: Trial registered
  2. 13 Sep 2024: Trial started
  3. 21 Nov 2025: Trial completed

NCT06649045: A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

State
Completed
Phase
Phase 3
People
712 taking part
Started
22 Oct 2024
Primary completion
21 Jul 2026
Arms
Orforglipron
Results
None posted
  1. 18 Oct 2024: Trial registered
  2. 22 Oct 2024: Trial started
  3. 30 Jul 2026: Trial completed

NCT06672939: A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

State
Under way
Phase
Phase 3
People
150 planned
Started
18 Nov 2024
Primary completion
Dec 2027
Arms
Orforglipron
Results
None posted
  1. 4 Nov 2024: Trial registered
  2. 18 Nov 2024: Trial started

NCT06824051: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight

State
Completed
Phase
Phase 1
People
120 taking part
Started
17 Feb 2025
Primary completion
26 Jan 2026
Arms
Orforglipron
Results
None posted
  1. 13 Feb 2025: Trial registered
  2. 17 Feb 2025: Trial started
  3. 26 Jan 2026: Trial completed

NCT06948435: A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

State
Under way
Phase
Phase 3
People
487 planned
Started
30 Apr 2025
Primary completion
Sep 2027
Arms
Orforglipron
Results
None posted
  1. 29 Apr 2025: Trial registered
  2. 30 Apr 2025: Trial started

NCT06972459: A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

State
Under way
Phase
Phase 3
People
800 planned
Started
15 May 2025
Primary completion
Aug 2027
Arms
Orforglipron Dose 1, Orforglipron Dose 2, Orforglipron Dose 3, Orforglipron Dose 4
Results
None posted
  1. 15 May 2025: Trial registered
  2. 15 May 2025: Trial started

NCT06972472: A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

State
Under way
Phase
Phase 3
People
600 planned
Started
19 May 2025
Primary completion
Aug 2027
Arms
Orforglipron Dose 1, Orforglipron Dose 2, Orforglipron Dose 3, Orforglipron Dose 4
Results
None posted
  1. 15 May 2025: Trial registered
  2. 19 May 2025: Trial started

NCT06993792: A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

State
Under way
Phase
Phase 3
People
1,400 planned
Started
15 May 2025
Primary completion
Aug 2027
Arms
Orforglipron Dose 1 (Study GZP1), Orforglipron Dose 2 (Study GZP1), Orforglipron Dose 3 (Study GZP1), Orforglipron Dose 4 (Study GZP1), Orforglipron Dose 1 (Study GZP2), Orforglipron Dose 2 (Study GZP2), Orforglipron Dose 3 (Study GZP2), Orforglipron Dose 4 (Study GZP2)
Results
None posted
  1. 15 May 2025: Trial started
  2. 29 May 2025: Trial registered

NCT07153471: A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

State
Under way
Phase
Phase 3
People
800 planned
Started
15 Sep 2025
Primary completion
Apr 2028
Arms
Orforglipron (GZT1), Orforglipron (GZT2)
Results
None posted
  1. 4 Sep 2025: Trial registered
  2. 15 Sep 2025: Trial started

NCT07790861: A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems

State
Not started
Phase
Phase 3
People
192 planned
Started
Dec 2026
Primary completion
Mar 2028
Arms
Orforglipron
Results
None posted
  1. 27 Aug 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.